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ABSTRACT
Literature regarding toxic optic neuropathy (TON) due to isoniazid (INH) is scarce. This diagnosis is often missed, leading to unnecessary delay in 
institution of corrective measures. Often, this delay can worsen the patient’s vision, with a high likelihood of development of serious damage to the 
patient’s vision. We report a case of a 49-year-old gentleman, afflicted with meningeal tuberculosis, who developed visual disturbances following the 
administration of antitubercular therapy. The patient’s vision improved dramatically following INH’s withdrawal. This case highlighted the need to 
keep INH as a possible cause for TON, especially if vision does not improve following ethambutol’s withdrawal. Further, this case attests to the need 
for thorough and periodic visual examinations in patients receiving antitubercular therapy.
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INTRODUCTION
Tuberculosis caused by Mycobacterium tuberculosis complex is an 
airborn infection in 80% of cases [1]. It is a contagious infection 
affecting wide range of population in low income and developing 
countries with India being highest burden country in the world [2]. 
Various drug regimens are used to treat tuberculosis which includes 
isoniazid (INH), rifampicin, pyrazinamide, INH, and streptomycin used 
as first-line agents. Adverse drug reactions due to tuberculosis are very 
common as these drugs are given for a longer period ranging from 
6 months to 2 years depending on the course of illness and diagnosis 
at the first place. Optic neuropathy, due to antitubercular drugs, has 
rarely been attributed to INH. An extensive literature search revealed 
only a handful of cases, where INH has been implicated as the causative 
agent for optic neuropathy [3,4]. Given that ethambutol is the more 
commonly associated antitubercular agent with optic neuropathy [5], 
the odds of overlooking INH as the offending agent is extremely high. 
The resultant delay in arriving on the appropriate diagnosis could 
manifest in serious damage to the patient’s vision, maybe even optic 
atrophy. Further, given that the incidence of tuberculosis overall and 
particularly, meningeal tuberculosis is extremely high, especially in the 
developing nations like India [6]; it is of imminent significance that a 
greater awareness of the INH induced ocular disturbances be created 
within the scientific community. Hence, with the aim of contributing 
to the existing literature, we report a case of INH induced toxic optic 
neuropathy (TON) in a tubercular patient in a tertiary care hospital in 
southern India.
CASE REPORT
Informed consent was taken from the patient. A 49-year-old gentleman, 
devoid of any other comorbidity, was diagnosed and initiated on the first 
line antitubercular treatment for tubercular meningitis since October 
30th, 2014. During the gentleman’s follow-up visit on January 23rd, 2015, 
he complained of sudden, painless blurring of vision of 4 days’ duration. 
Examination revealed features of abnormality of color vision and 
perimetry revealed central scotoma. As per ophthalmologist opinion 
optic neuritis due to ethambutol was suspected, and the drug was 
stopped. The gentleman was readmitted on February 21st, 2015, with 
complaints of paraparesis and cord involvement, with the worsening of 
his visual symptoms. Fundoscopic examination revealed worsening of 
the inflammation of the optic nerve, and visual acuity also was markedly 
reduced. Hence, in light of the worsening of the ophthalmological 
symptomatology, a decision to withdraw INH was taken. Further, a 
second line anti-tubercular agent, i.e., injection amikacin 750 mg and 
moxifloxacin 400 mg once daily was started. Subsequently, during the 
patient’s stay in the hospital over the next 10 days, there was drastic 
improvement in patient visual symptoms. The lack of change in the 
magnetic resonance imaging picture, before and post withdrawal of 
INH, further confirmed it to be a case of INH induced TON.
DISCUSSION
TON is one of the most underdiagnosed ophthalmologic conditions 
apparently diagnosed when the stage of irreversible vision loss is 
reached. Impairment of vision defines it due to damage caused to the 
optic nerve. Anterior pathway of eye is highly susceptible to damage 
via various toxins encountered in the workplace, eating some foods, 
ingesting toxins, and due to drugs without sex predilection across all 
populations. Reduced color vision, papillomacular bundle damage and 
central or cecocentral scotoma usually forms a triad in diagnosing TON. 
Various etiologies cause TON with both toxins and nutritional factors 
in tandem playing a synergistic role. It usually presents as bilateral, 
symmetrical painless loss of vision. Dyschromatopsia is usually the first 
presenting sign gradually leading to generalized loss of color perception. 
Loss of visual acuity usually starts as a relative scotoma slowly leading to 
total loss of vision with peripheral vision sparing. The one exception to 
this is acute loss of complete vision seen in cases of methanol poisoning. 
Various causes of TON are illustrated in Table 1. Pathogenesis behind 
TON is mainly impairment of vascular supply either to the optic nerve 
or to the papillomacular bundle. The optic nerve is highly susceptible 
to this ischemic damage due to its unusual configuration leading to 
accumulation of toxins; this remains unproven as of date. However, the 
common generalized mechanism accepted till date is mitochondrial 
damage and disturbance of physiological hemostasis [7].
Antitubercular medications are known to cause various side effects, 
and ophthalmic adverse effects have also been reported over the 
years. Ethambutol and INH causes optic neuropathies but TON due 
to ethambutol is very common when compared to INH. Ethambutol 
causes optic neuropathy in about 1-15% patients treated with it for 
tuberculosis. Proposed mechanism of ethambutol-induced TON is 
mainly through its zinc chelating property and its said to be due to the 
influx of calcium ions into the mitochondria leading to excitability [7]. 
It is usually dose dependent and optic neuropathy reverses itself 
on discontinuation of the drug. In a recent systemic review, as per 
literature, it was found that the incidence of ethambutol induced ocular 
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toxicity was 22.5 per 1000 persons treated with 4.3/1000 persons 
having permanent impairment [8].
INH-induced optic disturbances are less frequently reported. Sutton 
and Beattie described the first case of INH induced optic neuropathy. 
Jason and Bloke observed association of optic lesions in patients 
treated for tubercular meningitis with intrathecal INH. Incidence of 
INH-induced optic disturbances is not clearly known but so far 11 cases 
of INH-induced TON have been reported in literature. Mechanisms 
postulated are mainly due to disturbances in pyridoxine metabolism. 
It is considered that the mechanism of optic neuritis due to INH is due 
to loss of pyridoxine in urine and also inhibition of pyridoxal phosphate 
which blocks neurotransmitters. It is dose dependent, with total doses 
ranging from 2 to 108 g, causing optic neuropathies. INH-induced optic 
neuropathy usually starts with 10 days of start of INH treatment but 
can occur also after a period of 2-3 months. Discontinuation of INH is 
highly warranted and reversibility of vision occurs quickly in 4 days 
but complete recovery takes 4 weeks. Very rarely it takes 6 months for 
reversing. Failure to stop INH results in optic atrophy [9-11].
In our case, the patient complained of vision abnormalities within 
3 months of initiation of antitubercular therapy. Initially, ethambutol 
was suspected as the offending agent, and the drug was discontinued. 
Subsequently, the gentleman’s vision worsened. Hence, INH was 
suspected as the next possible cause for the visual deterioration and 
discontinued. The patient improved drastically on stopping INH. 
Tuberculosis associated optic nerve damage was ruled out as patient 
did not have any other associated optic conditions such as retinitis 
and uveitis. It is similar to previous reports suggesting incidence of 
optic lesions in tubercular meningitis patients treated with INH and 
also total dose is 54 g which is well within the dose range reported to 
cause optic neuropathy. Other supporting factors are patient recovering 
immediately after discontinuation having similarity to the other case 
reports in literature. Hence, to establish a definite causal relationship, 
Naranjo’s [12] causality was done and possible causality was ascribed. 
Adverse reaction was moderately severe as per Hartwig’s scale [13] and 
was not preventable as per Thornton’s scale (Table 2) [14].
CONCLUSION
As TON, due to INH is a rare phenomenon, a thorough visual 
assessment needs to be done before and periodically subsequent to 
the initiation of the antitubercular therapy. The patients should be 
educated about the possibility of development of ophthalmological 
symptoms. Further, on developing visual disturbances, patients 
should be encouraged to report to the physician at the earliest so 
that corrective measures can be instituted in time. The physicians 
should keep in mind the possibility of INH besides ethambutol as 
the possible offending agent for TON. An elementary measure like 
withdrawal of the suspected drug can go a long way in reversing the 
visual symptoms. Moreover, as pyridoxine deficiency has been found 
to be associated with a large number of INH induced optic neuropathy 
cases, pyridoxine supplementation may also be carried out for such 
to prevent neurological complications. Further, in a bid to determine 
the burden of INH-induced ocular disturbances, well-designed 
prospective studies are the need of the hour in India.
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Table 1: Causes of TON
Antimalarials Chloroquine, quinine
Antibiotics Sulfonamides, chloramphenicol, linezolid
Anticancer Vincristine, methotrexate
Antitubercular Ethambutol, INH, streptomycin
Heavy metals Mercury, lead, thallium
Antiarrythmics Digoxin, amiodarone
Others Tobacco, carbon monoxide
TON: Toxic optic neuropathy, INH: Isoniazid
Table 2: Adverse drug assessment
Scales Assessment
Naranjo’s Possible
Hartwig’s Moderate severity
Thornton’s Not preventable
